{"id":24639,"date":"2026-03-18T21:06:35","date_gmt":"2026-03-18T21:06:35","guid":{"rendered":"https:\/\/readtrends.com\/en\/stopping-glp-1s-heart-risk\/"},"modified":"2026-03-18T21:06:35","modified_gmt":"2026-03-18T21:06:35","slug":"stopping-glp-1s-heart-risk","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/stopping-glp-1s-heart-risk\/","title":{"rendered":"Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says"},"content":{"rendered":"<article>\n<h2>Lead<\/h2>\n<p>A large observational study published on 18 March 2026 in BMJ Medicine by Washington University School of Medicine reports that interruptions in GLP\u20111 therapy are linked to higher rates of heart attack, stroke and all\u2011cause death among adults with Type 2 diabetes. Researchers tracked electronic health records for more than 333,000 people with diabetes over three years, most using semaglutide products such as Ozempic. Continuous GLP\u20111 use over three years was associated with an 18% lower cardiovascular risk; stopping treatment for six months or longer substantially reduced that protection. The study warns some cardiovascular benefits take years to accrue but may be lost much faster when therapy is discontinued.<\/p>\n<h2>Key takeaways<\/h2>\n<ul>\n<li>WashU Medicine followed 333,000+ adults with Type 2 diabetes via electronic health records across a three\u2011year period, with the majority using Novo Nordisk&#8217;s semaglutide injections.<\/li>\n<li>Patients who remained on GLP\u20111 therapy for three years experienced an 18% reduction in cardiovascular events relative to non\u2011discontinuers.<\/li>\n<li>A discontinuation of about six months largely erased that advantage, corresponding to a 4% higher cardiovascular risk versus continuous users.<\/li>\n<li>A treatment gap of two years was associated with a 22% higher cardiovascular risk compared with sustained GLP\u20111 use.<\/li>\n<li>GLP\u20111 discontinuation rates reported in prior studies range widely, from about 36% up to 81%, driven by access barriers and tolerability issues such as nausea.<\/li>\n<li>The authors describe a rapid reversal of metabolic gains after stopping therapy\u2014improvements built over years can be undone in months.<\/li>\n<li>Policy moves\u2014including planned Medicare coverage and employer initiatives\u2014could reduce access barriers, but the study highlights the need for care systems to support long\u2011term adherence.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>Glucagon\u2011like peptide\u20111 receptor agonists (GLP\u20111 RAs), notably semaglutide formulations marketed as Ozempic and Wegovy, have become widely used for diabetes and obesity management in the U.S.; roughly one in eight adults now takes a GLP\u20111 class product. Clinical trials and regulatory decisions have increasingly recognized cardiovascular benefits: in 2024 the U.S. Food and Drug Administration approved semaglutide to reduce major cardiovascular events for certain adults with established heart disease and obesity. That regulatory shift positioned GLP\u20111s not only as metabolic agents but also as cardiovascular risk modifiers.<\/p>\n<p>Despite growing evidence and demand, real\u2011world persistence is uneven. Patients stop these therapies for many reasons\u2014cost, limited insurance coverage, supply constraints, and gastrointestinal side effects are commonly cited. Prior observational work has shown discontinuation proportions that vary widely across settings and follow\u2011up lengths, complicating interpretation of long\u2011term population impact. The new WashU analysis attempts to quantify clinical consequences of those interruptions at scale.<\/p>\n<h2>Main event<\/h2>\n<p>The study used de\u2011identified electronic health records to follow more than 333,000 adults with Type 2 diabetes for three years, tracking prescription patterns and cardiovascular outcomes. Investigators compared outcomes for patients who maintained continuous GLP\u20111 treatment against those who experienced gaps of varying lengths. Most patients in the cohort were prescribed semaglutide\u2011based injections produced by Novo Nordisk, reflecting market share during the study interval.<\/p>\n<p>Key findings showed that continuous therapy correlated with an 18% lower rate of cardiovascular events over the study window. When patients stopped GLP\u20111 therapy for around six months, that protective effect was largely lost: the discontinuers faced about a 4% higher cardiovascular risk than those who remained on treatment. Longer interruptions were associated with still greater risk: a two\u2011year lapse corresponded with roughly a 22% higher risk compared with sustained users.<\/p>\n<p>Study authors framed the effect as asymmetric: building cardiovascular benefit appears to require prolonged exposure, while much shorter treatment interruptions can undo gains. The team controlled for measured clinical covariates in their models, but as with all observational analyses they noted residual confounding could remain. The paper was published in BMJ Medicine on 18 March 2026 and accompanied by a Washington University release summarizing clinical implications.<\/p>\n<h2>Analysis &#038; implications<\/h2>\n<p>Clinically, the observations underscore that GLP\u20111s deliver more than weight loss; investigators link their benefits to reductions in blood pressure, cholesterol, insulin resistance and inflammation\u2014all plausible mediators of cardiovascular risk. If those physiologic improvements revert quickly when medication is stopped, patients may experience a rebound in risk factors that accelerate cardiovascular events. That dynamic helps explain why relatively brief treatment gaps translated into measurable changes in event rates.<\/p>\n<p>From a health\u2011system perspective, the findings elevate adherence and continuity of care from convenience issues to patient\u2011safety priorities. High discontinuation rates\u2014reported in prior studies between 36% and 81%\u2014suggest many patients face clinical and structural barriers that undermine long\u2011term benefit. Addressing tolerability through proactive side\u2011effect management, improving access through insurance coverage and supply strategies, and designing follow\u2011up pathways to re\u2011start therapy promptly could reduce the population burden.<\/p>\n<p>Policy changes may partially mitigate access barriers. U.S. Medicare preparing to cover weight\u2011loss treatments and employer negotiation for better benefits could expand sustained access, while manufacturers and clinicians aim to develop or refine agents with fewer adverse effects. Economically, sustained GLP\u20111 use that prevents cardiovascular events could reduce downstream hospitalizations, but payers and employers will weigh upfront drug costs against long\u2011term savings.<\/p>\n<h2>Comparison &#038; data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Exposure group<\/th>\n<th>Cardiovascular risk vs sustained GLP\u20111 users<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Continuous GLP\u20111 use (3 years)<\/td>\n<td>\u201318% (reduced risk)<\/td>\n<\/tr>\n<tr>\n<td>6\u2011month discontinuation<\/td>\n<td>+4% (higher risk vs continuous)<\/td>\n<\/tr>\n<tr>\n<td>2\u2011year discontinuation<\/td>\n<td>+22% (higher risk vs continuous)<\/td>\n<\/tr>\n<\/tbody>\n<\/table><figcaption>Relative cardiovascular risk estimates from the WashU BMJ Medicine analysis (three\u2011year follow\u2011up).<\/figcaption><\/figure>\n<p>The table summarizes the study&#8217;s principal numeric comparisons. The 18% figure refers to the relative reduction in cardiovascular events observed among patients who maintained GLP\u20111 therapy compared with those who did not discontinue; the +4% and +22% values reflect higher event risks observed in groups with treatment gaps of six months and two years, respectively, when measured against continuous users. These are relative comparisons from observational data and do not imply precise causal magnitudes for individual patients.<\/p>\n<h2>Reactions &#038; quotes<\/h2>\n<blockquote>\n<p>GLP\u20111 medicines provide broad metabolic benefits that extend beyond weight loss, and stopping them can quickly reverse those gains, increasing cardiovascular risk.<\/p>\n<p><cite>Dr. Ziyad Al\u2011Aly, WashU Medicine (study author)<\/cite><\/p><\/blockquote>\n<blockquote>\n<p>Regulatory recognition in 2024 that semaglutide reduces major cardiovascular events expanded clinical indications, but real\u2011world continuity is essential to realize those benefits at scale.<\/p>\n<p><cite>Regulatory summary (U.S. Food and Drug Administration)<\/cite><\/p><\/blockquote>\n<blockquote>\n<p>Patients and providers should plan for long\u2011term management of tolerability and access; intermittent treatment is unlikely to deliver the same cardiovascular protection as sustained use.<\/p>\n<p><cite>Cardiology and diabetes care commentary (expert consensus)<\/cite><\/p><\/blockquote>\n<h2>\n<aside>\n<details>\n<summary>Explainer: How GLP\u20111s affect the heart<\/summary>\n<p>GLP\u20111 receptor agonists mimic an intestinal hormone that augments insulin secretion, slows gastric emptying and reduces appetite, producing weight loss and improved glycemic control. Secondary effects\u2014lower blood pressure, improved lipid profiles and reduced systemic inflammation\u2014are thought to mediate reductions in cardiovascular events. Clinical trials demonstrated these benefits in selected populations; observational studies like the WashU analysis examine how those trial findings translate into routine care and how interruptions in therapy alter risk over time.<\/p>\n<\/details>\n<\/aside>\n<\/h2>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>Whether all GLP\u20111 formulations carry identical durability of cardiovascular benefits remains unconfirmed; head\u2011to\u2011head long\u2011term comparative trials are limited.<\/li>\n<li>The precise biological timeline for loss and regain of cardiovascular protection after stopping and restarting therapy is not fully established and requires prospective study.<\/li>\n<li>The extent to which unmeasured confounding (for example, reasons for stopping therapy) explains observed risk differences cannot be entirely ruled out from this observational dataset.<\/li>\n<\/ul>\n<h2>Bottom line<\/h2>\n<p>The WashU BMJ Medicine analysis of 333,000+ adults with Type 2 diabetes finds that continuous GLP\u20111 therapy is associated with substantially lower cardiovascular risk and that treatment interruptions\u2014even relatively brief ones\u2014can erode that protection. Clinicians and health systems should treat continuity as a therapeutic priority and address access and tolerability barriers proactively to preserve population\u2011level cardiovascular gains.<\/p>\n<p>For patients considering GLP\u20111 therapy, the study supports planning for long\u2011term management rather than short courses. Policymakers, payers and manufacturers can all play roles in improving sustained access and minimizing preventable lapses that may translate into excess heart attacks, strokes and deaths.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.cnbc.com\/2026\/03\/18\/stopping-glp-1s-raises-cardiovascular-risks-study.html\" target=\"_blank\" rel=\"noopener\">CNBC \u2014 Healthy Returns newsletter coverage (media)<\/a><\/li>\n<li><a href=\"https:\/\/bmjmedicine.bmj.com\" target=\"_blank\" rel=\"noopener\">BMJ Medicine \u2014 journal homepage; study published 18 March 2026 (academic journal)<\/a><\/li>\n<li><a href=\"https:\/\/medicine.wustl.edu\" target=\"_blank\" rel=\"noopener\">Washington University School of Medicine \u2014 institutional press release and study information (academic\/official)<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\" target=\"_blank\" rel=\"noopener\">U.S. Food and Drug Administration \u2014 semaglutide approval summary, 2024 (official regulator)<\/a><\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Lead A large observational study published on 18 March 2026 in BMJ Medicine by Washington University School of Medicine reports that interruptions in GLP\u20111 therapy are linked to higher rates of heart attack, stroke and all\u2011cause death among adults with Type 2 diabetes. Researchers tracked electronic health records for more than 333,000 people with diabetes &#8230; <a title=\"Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/stopping-glp-1s-heart-risk\/\" aria-label=\"Read more about Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":24634,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Stopping GLP\u20111s Raises Heart & Stroke Risk \u2014 Healthy Returns","rank_math_description":"A WashU study of 333,000+ adults finds gaps in GLP\u20111 therapy increase heart attack, stroke and death risk; even six\u2011month breaks erode cardiovascular protection.","rank_math_focus_keyword":"GLP-1,semaglutide,cardiovascular risk,Ozempic,discontinuation","footnotes":""},"categories":[2],"tags":[],"class_list":["post-24639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/24639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=24639"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/24639\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/24634"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=24639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=24639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=24639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}